moneyheap
ZLAB · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Zai Lab Limited American Depositary Shares (ZLAB) stock moving?
Zai Lab reported Q3 2026 results on Nov 5 that beat consensus: total revenue of $108.2M versus a $105.8M estimate, and EPS of $(0.04) versus $(0.07). Net product revenue grew only 2% sequentially, so management is pointing to a return to meaningful growth in 2027 rather than current momentum. The company presented updated zoci data at the NANETS symposium and cited an 81.8% confirmed ORR and an estimated 81.9% six-month PFS rate in first-line SCLC at ESMO, with 9.1% Grade 3 treatment-related AEs, and it is moving toward a global Phase 3. Key timing points are a possible DLLEVATE interim analysis in H2 2027, a 2L epNEC data readout in H1 2027, and first ZL-1503 atopic dermatitis patient data in H1 2027. Funding was addressed by a $250M PIPE at $22.04 per ADS (11.34M ADSs, led by TCGX, closing around Oct 27) for zoci development. The stock closed at $22.60 on Nov 5 and rose 12.8% to $25.48 on Nov 6 on volume of 1.89M, versus roughly 0.5-0.8M in late October. It peaked intraday at $29.02 on Nov 9 and closed at $26.43 on Nov 10, so most of the post-earnings gain has held while the shares have pulled back from the high. The shares now trade about 20% above the PIPE price, which could make the planned resale registration an added supply source. The main offsets are continued losses, slow near-term revenue growth, and the fact that the big clinical catalysts sit mostly in 2027.
News behind the analysis
- Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society SymposiumZai Lab presented updated Phase 1b/2 data for its DLL3-targeting ADC zocilurtatug pelitecan (zoci) in previously treated extrapulmonary neuroendocrine carcinomas, describing durable anti-tumor responses.
- Zai Lab Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $108.208M Beat $105.825M EstimateZai Lab reported third-quarter 2026 EPS of $(0.04) versus a $(0.07) estimate and sales of $108.2M versus a $105.8M estimate.
- Zai Lab Q3 2026 Earnings Call TranscriptTranscript of the Q3 2026 earnings call, where management outlined the zoci development path in small cell lung cancer and the expected return to growth in China in 2027.
About Zai Lab Limited American Depositary Shares
Zai Lab is a biopharmaceutical company based in Shanghai and Cambridge, Massachusetts. Its shares trade on Nasdaq as ADSs and on the Hong Kong exchange (9688). It sells licensed medicines in Greater China and is also trying to become a global drug developer. Its main experimental drug is zocilurtatug pelitecan (zoci), an antibody-drug conjugate that targets the DLL3 protein in small cell lung cancer and neuroendocrine cancers.
How it makes money
Most of its revenue comes from selling drugs in China that it licensed from Western partners. These include VYVGART (efgartigimod, from argenx), ZEJULA (niraparib) and the newly launched COBENFY. Quarterly revenue is roughly $100–110 million, about $108 million in Q3 2026. The sales business is profitable on its own, but research spending keeps the company as a whole loss-making, with a net loss of roughly $45–50 million per quarter. It pays for this with cash on hand, about $660 million at September 30, 2026, plus share sales such as an approximately $250 million private placement in October 2026.
What usually moves ZLAB
- Clinical trial results and regulatory progress for zoci (DLL3 ADC)
- China sales of VYVGART and ZEJULA, and pricing on China's national drug reimbursement list (NRDL)
- Cash burn and share issuance
- US–China political and regulatory tensions affecting Chinese biotech stocks
- Partnership and licensing deals